Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24308688 | 0.88 | GAA (0.47) | GAASMN1; SMN2ALDH1A1ACKR3MEN1 | |
| SCHEMBL18390110 | 0.84 | GAA (0.48) | GAASMN1; SMN2ALDH1A1ACKR3MEN1 | |
| SCHEMBL20349560 | 0.80 | SMN1; SMN2 (0.43) | GAASMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL19230133 | 0.80 | LMNA (0.44) | GAASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL16727368 | 0.77 | POLB (0.58) | GAASMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL18714403 | 0.76 | SMN1; SMN2 (0.47) | GAASMN1; SMN2ALDH1A1ACKR3L3MBTL1 | |
| SCHEMBL20381981 | 0.73 | RET (0.37) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL20381982 | 0.72 | RET (0.39) | GAASMN1; SMN2ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL18284698 | 0.72 | ACACB (0.45) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL20970520 | 0.71 | KMT2A (0.51) | GAASMN1; SMN2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | GAA 3356/4885SMN1; SMN2 1094/4885ALDH1A1 3241/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | GAA 3426/4885SMN1; SMN2 1115/4885ALDH1A1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.